This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kunicki, T. J. Search for Related Content PubMed PubMed Citation Articles by Kunicki, T. J. Related Collections Arterial thrombosis Thrombosis risk factors Platelets

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:14.)
© 2002 American Heart Association, Inc.

Brief Reviews

The Influence of Platelet Collagen Receptor Polymorphisms in Hemostasis and Thrombotic Disease

Thomas J. Kunicki

From The Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis of the Department of Molecular and Experimental Medicine and the Department of Vascular Biology, The Scripps Research Institute, La Jolla, Calif.

Address correspondence to Thomas J. Kunicki, PhD, Associate Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N Torrey Pines Rd, Maildrop: MEM 150, La Jolla, CA 92037. E-mail tomk{at}scripps.edu

	Abstract

Top Abstract Introduction Clinical Relevance of GPIb... Stable Adhesion to Collagens... Summary References

 
Extracellular collagens modulate the rate of platelet activation and thereby markedly influence hemostasis and thrombosis. Platelet receptors for collagens, such as the integrin ₂ß₁, platelet glycoprotein (GP) VI or, indirectly, the GPIb complex, are unexploited targets of pharmacological control, and polymorphisms of these receptors have recently become factored into the genetic risk for thrombosis. Seemingly contradictory findings already exist with regard to the contribution of GPIb and integrin ₂ polymorphisms, but these discrepancies will be resolved once there is better standardization of clinical studies. There is already substantial evidence that GPIb VNTR A or B alleles, the GPIb-5C allele, and integrin ₂ allele 1 (T₈₀₇) each contribute to increased risk for morbidity in thrombotic disease. However, larger, prospective genetic and epidemiological studies are needed to clarify the role of each of these polymorphisms, the contribution of other platelet receptor polymorphisms, and the synergistic effects of combinations of these factors. In addition, in vitro studies that establish the functional relevance of these polymorphisms will provide sound biological explanations for the results of clinical correlation studies.

Key Words: platelet • collagen • integrin • GPVI • thrombosis

	Introduction

Top Abstract Introduction Clinical Relevance of GPIb... Stable Adhesion to Collagens... Summary References

 
The importance of thrombosis as a health hazard cannot be overestimated. Ischemic heart disease and cerebrovascular disease are the leading causes of morbidity and mortality among both men and women in the developed western world.^1–4 Recent evidence indicates that the incidence of this disease is steadily increasing among Asian populations,⁵ and cardiovascular disease is now the leading cause of death among native American Indians.⁶ Epidemiological studies indicate that these diseases result from complex interactions between genetic susceptibility factors, chronic environmental influences (for example, hormonal imbalance, smoking, or obesity), and established, intercurrent disorders (such as diabetes, hypertension, dyslipidemia, or hyperhomocysteinemia). The most devastating complication of these disorders is acute myocardial infarction, resulting from the formation of an occlusive thrombus at the site of a ruptured atherosclerotic plaque. The critical role of platelets in this process is now well-accepted.⁷

At the same time, efficient platelet cohesion is necessary for the life-saving process of hemostasis. The rate of platelet activation is one important variable that contributes to the selection of these very different outcomes. Collagen is an important modulator of platelet activation through its stimulation of at least three platelet receptors. Platelets have two major primary receptors for collagens, the integrin ₂ß₁ and the platelet-specific receptor glycoprotein (GP) VI. A third receptor that figures prominently at the very onset of adhesion, the GPIb complex, is not usually thought of as a collagen receptor. Nonetheless, it is collagen that captures the von Willebrand Factor (VWF) molecule by binding to most likely its A3 domain, thereby localizing it and somehow altering its conformation to make it bind via its A1 domain with greater avidity to the GPIb complex. This interaction is relatively weak and short in duration, resulting in a slowing of platelet motion and a tethering or rolling of the platelet across the thrombogenic collagen-rich surface. It is at this point that the two major receptors, ₂ß₁ and GPVI, become involved. GPVI binds to collagens, albeit weakly, and plays an important role in transduction of signals leading to platelet activation. The more avid stable platelet attachment afforded by ₂ß₁ leads to a stable monolayer of activated platelets that serves as a nidus for prothrombin conversion and thrombus formation.

There are a number of additional aspects of the platelet-collagen interaction that are relevant. Like many integrins, ₂ß₁ can also undergo activation-dependent increases in avidity for collagens.⁸ Because the binding of VWF to the GPIb complex is known to activate another platelet integrin, _IIbß₃, it is conceivable that it may also activate ₂ß₁. In addition, an overly simplistic model wherein GPVI functions in signal transduction while ₂ß₁ merely mediates attachment would overlook the important contribution of ₂ß₁ to signal transduction in the absence of GPVI.^9–11

Plaque rupture and/or endothelial damage leads to exposure of collagens, retention of VWF, and the adhesion of circulating platelets to the damaged vessel wall, largely via the receptors described above. In the process, the platelet is activated leading to a conformational change of a second integrin _IIbß₃ that facilitates fibrinogen binding and platelet aggregation. Thrombin generated at the blood-plaque interface converts fibrinogen to fibrin, which stabilizes thrombus growth. Therefore, any genetic differences that might alter surface expression or activity of the primary collagen receptors could influence risk for adverse outcomes as a result of the hemostatic process. In the last five years, there has been a rapid accumulation of literature concerning the relationship between genetic variations in platelet glycoproteins and risk for coronary heart disease.

This review will focus mainly on the nature of GPIb and integrin ₂ polymorphisms and how they might contribute to the regulation of hemostasis and thrombosis. It will also briefly touch on the diversity in expression of GPVI, and how this might be related to expression of ₂. However, none of these platelet receptors acts in a vacuum in vivo, and the synergy between genetic differences in these and other key receptors needs to be considered.

	Clinical Relevance of GPIb Polymorphisms

Top Abstract Introduction Clinical Relevance of GPIb... Stable Adhesion to Collagens... Summary References

 
The GPIb complex is a heptamer composed of four distinct gene products: two molecules of GPIb, two of GPIbß, two of GPIX, and one of GPV. VWF is directly bound by the GPIb subunits, each of which is disulfide-linked to a GPIbß subunit. To date, all of the potentially relevant polymorphisms of the GPIb complex have been associated with the GPIb subunit.

The function, expression, and immunogenicity of the GPIb complex is influenced by each of three GPIb polymorphisms (Figure 1). The first involves a variable number of tandem repeats (VNTR) within the mucin-like macroglycopeptide region of GPIb, resulting in the duplication of a 13-amino acid sequence once (VNTR D), twice (VNTR C), thrice (VNTR B), or four times (VNTR A). This produces a polypeptide length of 610, 623, 636, or 649 amino acids, respectively.^12,13 Each repeat could add up to 32 angstroms to the length of the GPIb extracellular domain, because these repeats are rich in proline, serine, and threonine (Thr) and can become glycosylated.¹² In a simple model, yet to be proved, this could extend the GPIb binding sites for VWF and thrombin further above the plane of the plasma membrane, increasing the avidity for these ligands and accounting for the observed increased risk for acute coronary artery disease associated with the longer variants.^14,15

View larger version (52K): [in this window] [in a new window]   Figure 1. Polymorphisms of the GPIb Subunit. Three polymorphisms are relevant to the expression and function of GPIb. Top, VNTR polymorphism is characterized by the expression of four (VNTR A; not shown), three (VNTR B), two (VNTR C) or one (VNTR D) copy of a 39-base pair repeat sequence. In a typical white population, the gene frequencies of each allele are: A (<0.01), B (0.07), C (0.82), and D (0.11). Another dimorphism, the Met/Thr at residue 145 (nucleotide T/C substitution), gives rise to the Koa and Kob alloantigens and is linkage disequilibrium with the VNTR polymorphism. Thus, the VNTR A and B alleles express only Met-145, whereas the VNTR C and D alleles express only Thr-145. Bottom, In GPIb, a C/T substitution at a position five nucleotides upstream from the ATG start codon influences an adjacent Kozak sequence and thus the rate of translation of the mRNA transcript by the cell machinery. On average, the relationship of GPIb levels to genotype at this position is: T/T=1.0; T/C= 1.3; C/C=1.5.

The second GPIb polymorphism, a Thr/methionine (Met) substitution at amino acid 145, lies within the region of the ligand-binding, leucine-rich motifs (LRM),^16,17 and is the basis of the HPA-2 (Ko) platelet alloantigen system (Figure 1). The gene frequencies of the Thr and Met alleles in a typical white population are 90% and 10%, respectively.^16,17 The Thr/Met dimorphism is in linkage disequilibrium with the VNTR polymorphism, such that, among white people, the VNTR A and B alleles express Met-145, whereas the VNTR C and D alleles express Thr-145.

It seems logical that subtle changes in the avidity of GPIb for the VWF molecule could influence the rate of thrombosis in vivo, because of the key role of this receptor in the initiation of collagen dependent adhesion. Such an association has been found between inheritance of the Met-145 allele and risk for coronary artery disease^14,15 or stroke^15,18 in younger individuals. However, there has not been a universal confirmation of this finding, based on several additional reports.^19–27 These inconsistencies may be explained by the unaccounted for contribution of additional polymorphisms.

The final polymorphism of GPIb represents a T/C substitution in the region of the translation start site, at a position 5 nucleotides upstream (-5) from the initiator codon (ATG) (Figure 1). In platelets,^28,29 the presence of the -5C allele (gene frequency of 0.15 in various western populations) increases the mean level of GPIb on the platelet plasma membrane (roughly, a 50% increase in homozygous individuals, and a 33% increase in heterozygous individuals) presumably because it enhances the interaction of the cellular protein translation machinery to the adjacent Kozak sequence.²⁸ Although a number of clinical studies initially failed to show an association of the -5C allele with increased risk for development of acute coronary artery disease, more recent reports paint a different picture. There may well be an association between -5C and the severity of negative outcomes after acute myocardial infarction in younger individuals (62 years old).³⁰ Moreover, a recent study has documented a synergistic effect of -5C and Met-145 that results in an increased risk for stroke in younger individuals.³¹

	Stable Adhesion to Collagens Mediated by Integrin 2ß1 and GPVI

Top Abstract Introduction Clinical Relevance of GPIb... Stable Adhesion to Collagens... Summary References

 
The Human ₂ Gene
The integrin ₂ subunit is a single chain transmembrane polypeptide that pairs exclusively with the ß₁ subunit. In humans, a single copy of the ₂ gene (ITGA2) is present in the haploid genome, located on the short arm of chromosome 5 (5p11.12).³² An earlier study had incorrectly located the gene on the long arm of this chromosome at 5q23 to 31.³³ It is now also apparent that ITGA2 is situated very close to and immediately downstream from the integrin ₁ gene (ITGA1). This is important to our understanding of the transcriptional regulation of both of these genes. As depicted in Figure 2, ITGA1 (170 kb in length) and ITGA2 (110 kb in length) are separated by only 32 kb. Three independently defined chromosomal tags are situated in this same locus: D5S2092 is located roughly 44 kb upstream from the ITGA1 start codon; D5S623 is located at the very beginning of ITGA2 intron 1; and D5S2037 is situated about 420 kb downstream from the ITGA2 stop codon.

View larger version (9K): [in this window] [in a new window]   Figure 2. The human integrin ITGA1-ITGA2 locus on chromosome 5p11 to 12. The integrin 1 gene (ITGA1) is roughly 170 kb in length and is separated by only 32 kb from the integrin 2 gene (ITGA2; 110 kb in length) on a discrete segment of the short arm of human chromosome, proximal to the centromere (5p11 to 12). In this schematic, drawn to scale, the positions of the key sequence-tagged sites (STS) D5S2092, D5S623, and D5S2037 are used as landmarks to localize the ITGA1 and ITGA2 genes.

The ITGA2 cDNA sequence published by Takada and Hemler³⁴ was nearly complete, lacking the bulk of the final exon 30 and a polyadenylation site. We have subsequently completed the ₂ cDNA sequenced and located the polyadenylation site.³² These findings establish that ITGA2 exon 30 is unusually large (4.1 kb), larger than the combined size of the first 29 exons.

The initial published signal sequence of human ITGA1 is incorrect, albeit 100% identical to the rat ITGA1 signal sequence.³⁵ We have subsequently reported the correct human ITGA1 signal sequence.³²

₂ Polymorphisms
There is, on average, a 4-fold range in platelet ₂ß₁ density among randomly selected individuals, and these differences correlate directly with platelet adhesiveness to type-I or type-III collagens. This relationship cannot be explained by differences in mean platelet volume, because these vary by no more than 20%.^36,37 On the other hand, platelet ₂ß₁ density does correlate with and likely results from the inheritance of different alleles of the _2,^38,39 summarized schematically in Figure 3. Three major ₂ alleles can be defined. Allele 1 (807T/1648G/2531C) is associated with increased levels of ₂ß₁, whereas Allele 2 (807C/1648G/2531C) and Allele 3 (807C/1648A/2531C) are each associated with decreased levels of this receptor. The gene frequencies of these three alleles in a typical white population are: Allele 1, 0.394; Allele 2, 0.529; and Allele 3, 0.076. Within the coding sequence, two single-point missense dimorphisms have been described: A₁₆₄₈G (Lys₅₀₅Glu) and C₂₅₃₁T (Thr₇₉₉Met), that are responsible for the formation of the Br^a/Br^b (HPA-5) and Sit^a alloantigens (HPA-12bw), respectively.^40,41 Neither of these dimorphisms is causally involved in inherited expression differences. The rate of platelet attachment to type I collagen in whole blood under conditions of high shear rate (1,500/s) is proportional to the density of ₂ß₁ receptors on the platelet surface, as determined by differential inheritance of alleles 1, 2 or 3 (Figure 3). These initial findings suggested that ₂ alleles could influence risk of thrombosis or bleeding in relevant disease states.

View larger version (32K): [in this window] [in a new window]   Figure 3. Integrin 2 polymorphisms. Left, Three common 2 alleles can be distinguished by the silent 807 C/T dimorphism within exon 7 and the presence of unique Bgl II or Ase I restriction sites within the intron separating exons 7 and 8. The gene frequencies of each of these alleles in a typical white population are: allele 1=0.36; allele 2=0.56; and allele 3=0.08. Right, The relative level of platelet 2ß1 is controlled by the inheritance of these three 2 alleles. For example, individuals who are homozygous for 2 allele 1 (1,1) express, on average, 4-fold the amount of this receptor that would be found on platelets of individuals who are homozygous for 2 allele 2 (2,2).

Transcriptional Regulation of the ₂ Gene
The first 961 bp of the 5' flanking region of ₂ gene Allele 2 isolated from the K562 cell line directs tissue- specific suppressor and enhancer activity.^42,43 Within this region, the TATA-less core promoter () contains three Sp1 elements that are necessary for full transcription activity in erythro-megakaryocytic cell lines, such as Dami (a subclone of HEL), CHRF 288 to 11, or K562.^44–46 The distal 5' region contains a strong megakaryocytic enhancer located at that requires two tandem AP1 binding sites.⁴⁷

The continuum of differences in platelet ₂ß₁ density among normal individuals belies a simple gene dosage effect and suggests the influence of additional, unlinked genetic factors. Not surprisingly, we have identified inherited, single-base substitutions at two positions, C_-52T and C_-92G, within the proximal 5'-regulatory region (within -1096 to +48) of the human integrin ₂ gene.^45,46 The T_-52 and G_-92 sequences have a gene frequency of 0.35 and 0.15, respectively, in a typical white population. The substitutions T_-52 and G_-92 independently attenuate gene transcription, whereas the combination G_-92/T_-52 has an additive negative influence, in transfected human megakaryocytic cell lines. Thus, the natural dimorphisms C_-52T and C_-92G within the proximal 5'-regulatory region of the human integrin ₂ gene contribute to the regulation of integrin ₂ß₁ expression on megakaryocytes and blood platelets and must thereby modulate collagen-related platelet functions in vivo.

In the very common, but symptomatically mild, type 1 von Willebrand disease (VWD), platelet adhesive functions are impaired because of the decrease in VWF levels in plasma and platelets. DiPaola et al⁴⁸ have demonstrated that the low-density ₂ allele 2 increases the risk for bleeding in type I VWD. The frequencies of ₂ alleles in symptomatic patients with five types of VWD were measured (type 1, n=78; type 2A, n=25, type 2B, n=14; type 2 mol/L, n=10; and type 3, n=20). Compared with the normal group, no significant difference in allele frequencies was observed among individuals with types 2A, 2B, 2 mol/L, or 3 VWD. However, the frequency of allele 2 among type 1 VWD patients (= 0.71) was significantly higher than that of the normal population (P=0.007). Also, in patients with VWD type 1 and borderline to normal ristocetin-cofactor (VWF: RCo) activity values, collagen receptor density correlates inversely with closure time in a high shear stress system, the Platelet Function Analyzer (PFA-100; Dade-Behring). Thus, low platelet ₂ß₁ density results in less efficient primary platelet adhesion and may result in increased tendency to bleed, as evidenced by the high frequency of this polymorphism in patients with type 1 VWD compared with normal individuals. In addition, this may account for the variability between patients with similar levels of VWF antigen, but strikingly different bleeding histories.

Santoso et al⁴⁹ investigated the relationship of the ₂ alleles to the risk of coronary artery disease (CAD) and myocardial infarction (MI; Figure 4). DNA samples from 2237 male patients who underwent coronary angiography on account of coronary heart disease as verified illness or presumptive diagnosis were genotyped. A strong association between allele 1 and nonfatal MI was found among individuals younger than the mean age of 62 years (n=1057; odds ratio, 1.57; P=0.004), and an even stronger association existed among individuals within the youngest 10% of the study sample (<49 years; n=223; odds ratio, 2. 61; P=0.009). In contrast, no evidence of an association between ₂ alleles and CAD was found.

View larger version (36K): [in this window] [in a new window]   Figure 4. Correlation between Inheritance of the Integrin 2 Allele 1 (Increased 2ß1 Density) and Risk for Adverse Outcomes in Various Thrombotic Disorders. Individual studies that confirm (YES) or refute (NO) a correlation between inheritance of 2 allele 1 (807T genotype) and risk for thrombotic disease are indicated. The clinical syndromes include acute MI, cerebral vascular disease (CVD)/stroke, CAD, deep vein thrombosis (DVT), diabetic retinopathy, and venous thrombosis. Data are tabulated as of March 2001.

The significance of the C₈₀₇T dimorphism to arterial disease has been evaluated in several other studies (Figure 4). The initial reports described a correlation between allele 1 (T₈₀₇) (high receptor density) and risk for MI.^49,50 These have been confirmed by Roest et al⁵¹ who found that allele 1 (T₈₀₇) was associated with increased vascular mortality in women who are heavy, chronic smokers. In addition, a significant association was also found in younger patients with stroke⁵² and in patients with diabetic retinopathy.⁵³ On the other hand, some studies were unable to establish an association between allele 1 (T₈₀₇) and MI.^54–56 Conversely, in two of these studies,^54,55 the frequency of the homozygous TT genotype among the study controls was higher than that reported among normal white or Asian populations, respectively,^49,53 and it may have markedly influenced the conclusions. It is evident that patient and control selection bias needs to be eliminated from clinical studies of this kind by careful consideration of ethnic and racial influences on allele frequencies.

The Lys₅₀₅Glu amino acid substitution located in the cation-binding domain of ₂ is responsible for HPA-5b (Br^a) and HPA-5a (Br^b) epitope formation.⁴⁰ In a large study, Kroll et al⁵⁷ found an association between HPA-5 dimorphism in low-risk patient subgroup with CAD. In this population, the frequency of Br^b homozygous individuals was over-represented. This finding suggests that allele 3 (807C; Br^a) may increase risk for thrombotic disease through a qualitative effect on ₂ß₁ function that is independent of genetic effects on expression levels.

In contrast, the density of platelet ₂ß₁ has not been found to be a risk factor for venous thrombosis.^58–60 This lack of influence on thrombosis on the venous side is a typical finding for all of the platelet glycoprotein dimorphisms that are currently under study.

Platelet GPVI
GPVI is a major platelet glycoprotein (60- to 65-kDa) that had been considered a putative receptor for collagen since the identification of a patient with a mild bleeding disorder whose platelets lacked GPVI and exhibited defective collagen-induced responses.^61–63 Collagen binding to GPVI induces platelet activation through a pathway that involves phosphorylation of the FcR chain followed by the binding of Syk and the phosphorylation-dependent activation of PLC2.^64–67 The sequence of collagen that is recognized by GPVI has been identified as Gly-Pro-Hyp, and a synthetic collagen-related peptide (CRP) based on the triple helical form of this tripeptide sequence is a GPVI-specific platelet agonist.⁶⁸ The GPVI-Fc complex will transduce outside-in signals by an immune receptor-like mechanism that involves p72^SYK activation, results in PLC2 activation, and leads to release of granule contents and platelet aggregation.⁶⁹ The C-type lectin convulxin (CVX), from the tropical rattlesnake Crotalus durissus terrificus, is a multimeric protein that binds specifically to GPVI and induces platelet activation through the clustering of GPVI.^70,71 CVX is a ready tool for the detection and quantitation of GPVI that also proved invaluable for the isolation and eventual sequencing of this receptor.⁷² GPVI cDNA has an open reading frame of 1017 base pairs coding for a protein of 339 amino acids including a putative 23-amino acid signal sequence and a 19-amino acid transmembrane domain between residues 247 and 265. By sequence homology, GPVI is a member of the immunoglobulin superfamily, and its sequence is closely related to FcR and the natural killer receptors. It contains two Ig-C2-like domains formed by disulfide bridges. The cytoplasmic tail, consisting of 51 amino acids, is atypical of and shows little homology with the C-terminal part of the other members of this protein family.

To analyze the variability in platelet GPVI content between individuals, we developed a semiquantitative ligand blot assay in which biotin-conjugated CVX binds selectively to GPVI in separated total platelet proteins.⁷³ We observed a 5-fold range in platelet GPVI content among 23 normal healthy subjects that cannot be accounted for by differences in mean platelet volume between donors, because the latter variation is on the order of 20% to 30%.^36,37 In addition, we have determined that CVX- or CRP-induced prothrombinase activity is directly proportional to the platelet content of GPVI. In view of the well-documented association of GPVI with platelet procoagulant activity, the variation in GPVI content reported in this study suggests that variation in GPVI content may also contribute to risk for hemorrhagic or thromboembolic disorders.

Among our normal platelet donor panel, we found that the content of GPVI appears to parallel the density of ₂ß_1.⁷³ This intriguing and statistically significant correlation remains unexplained at this time. It is possible that these two receptors are physically associated at the platelet surface, and that the expression of one is dependent on the presence of the other, the density of the latter under genetic control. However, there is no evidence yet that this is the case. Nonetheless, it is possible that the expression of both receptors is regulated during megakaryocyte development by an independent gene product, perhaps a transcriptional factor, and that the levels of this third gene product are genetically controlled. Consistent with this possibility, Lagrue-Lak-Hal et al⁷⁴ have recently observed that the appearance of GPVI and ₂ß₁ is coordinated during human megakaryocyte maturation and both are expressed only on CD41⁺ cells. Because the levels of these receptors vary in parallel between individuals, it remains to be determined which of these receptors, if not both, is responsible for genetically-controlled differences in platelet responses to collagens.

Other Collagen Receptors
Additional receptors may contribute to the variability of donor responses to collagens. Early work by Chiang et al^75–77 identified a 65-kDa receptor that binds uniquely to type I collagen, and a 68- to 72-kDa receptor has been recently identified that binds preferentially to type III collagen.⁷⁸ The relative influence of these receptors on collagen-dependent platelet functions in vivo remains to be evaluated. More recently, the exciting possibility was raised that GPV might be involved in collagen responses. The precise contribution of GPV to platelet function has remained elusive, but the establishment of GPV^-/- mice may have uncovered an unexpected role for this receptor.⁷⁹ Platelets from these mice seem to have a defective response to collagen. This intriguing and unexpected observation warrants further investigation.

	Summary

Top Abstract Introduction Clinical Relevance of GPIb... Stable Adhesion to Collagens... Summary References

 
With regard to hemostasis and thrombosis, collagens are among the most important physiological components of the extracellular matrix in their role as platelet activators. Differences in the rate of platelet activation markedly influence normal hemostasis and the pathological outcome of thrombosis. Thus, collagen receptors, such as the integrin ₂ß₁ and, indirectly GPIb, represent a relatively unexploited target of pharmacological control and are only recently becoming appreciated as potential factors in the genetic risk for thrombosis. In general, the importance of platelet glycoprotein polymorphisms as genetic risk factors for arterial thrombosis is a new area of human genomics that needs to be carefully addressed. As was the case with previously proposed genetic risk factors, controversies and seemingly contradictory findings already exist with regard to GPIb and the integrin ₂. These discrepancies will only be resolved once there is a universal standard for clinical study design. Most of the clinical studies differ by patient population size, ethnicity, bias in the selection of patients and controls, plurality in clinical endpoints and variation of environmental factors. Despite these differences, there is substantial evidence that the GPIb VNTR A or B alleles, the -5C allele of GPIb, and allele 1 (T₈₀₇) of integrin ₂ each contribute to the risk for and morbidity of thrombotic disease. There may remain dispute as to the extent of their contribution. However, well-designed, large, prospective, genetic and epidemiological studies are needed to clarify the role of these and other platelet receptor polymorphisms. Additional in vitro studies of the functional relevance underlying these polymorphisms are needed to provide a sound biological explanation for the results of clinical correlations. The opportunity now exists to make significant inroads into the development of strategies for the prevention of thrombotic disease.

	Acknowledgments

Top Abstract Introduction Clinical Relevance of GPIb... Stable Adhesion to Collagens... Summary References

 
This study was supported by NHLBI Grant HL46979 awarded to T.J. Kunicki. The participation of the GCRC staff is gratefully acknowledged and was supported by USPHS Grant M01 RR00883.

Received August 14, 2001; accepted October 3, 2001.

	References

Top Abstract Introduction Clinical Relevance of GPIb... Stable Adhesion to Collagens... Summary References

 
1. Mortality from coronary heart disease and acute myocardial infarction-United States, 1998. MMWR Morb Mortal Wkly Rep. 2001; 50: 90–93.[Medline] [Order article via Infotrieve]

2. Bedinghaus J, Leshan L, Diehr S. Coronary artery disease prevention: what’s different for women? Am Fam Physician. 2001; 63: 1393–1396.[Medline] [Order article via Infotrieve]

3. Brass LM. The impact of cerebrovascular disease. Diabetes Obes Metab. 2000; 2 (suppl 2): S6–S10.[Medline] [Order article via Infotrieve]

4. Pellicano R, Oliaro E, Gandolfo N, Aruta E, Mangiardi L, Orzan F, Bergerone S, Rizzetto M, Ponzetto A. Ischemic cardiovascular disease and Helicobacter pylori: where is the link? J Cardiovasc Surg (Torino). 2000; 41: 829–833.[Medline] [Order article via Infotrieve]

5. Kauffmann-Zeh A, Dhand R, Allen L. Vascular biology. Nature. 2000; 407: 219.[CrossRef]

6. Harwell TS, Gohdes D, Moore K, McDowall JM, Smilie JG, Helgerson SD. Cardiovascular disease and risk factors in Montana American Indians and non-Indians. Am J Prev Med. 2001; 20: 196–201.[CrossRef][Medline] [Order article via Infotrieve]

7. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001; 134: 224–238.[Abstract/Free Full Text]

8. Jung SM, Moroi M. Platelets interact with soluble and insoluble collagens through characteristically different reactions. J Biol Chem. 1998; 273: 14827–14837.[Abstract/Free Full Text]

9. Kamiguti AS, Theakston RD, Watson SP, Bon C, Laing GD, Zuzel M. Distinct contributions of glycoprotein VI and ₂ß₁ integrin to the induction of platelet protein tyrosine phosphorylation and aggregation. Arch Biochem Biophys. 2000; 374: 356–362.[CrossRef][Medline] [Order article via Infotrieve]

10. Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight CG, Farndale RW, Okuma M, Barnes MJ. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood. 1998; 91: 491–499.[Abstract/Free Full Text]

11. Ichinohe T, Takayama H, Ezumi Y, Arai M, Yamamoto N, Takahashi H, Okuma M. Collagen-stimulated activation of Syk but not c-Src is severely compromised in human platelets lacking membrane glycoprotein VI. J Biol Chem. 1997; 272: 63–68.[Abstract/Free Full Text]

12. Lopez JA, Ludwig EH, McCarthy BJ. Polymorphism of human glycoprotein Ib results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region. J Biol Chem. 1992; 267: 10055–10061.[Abstract/Free Full Text]

13. Ishida F, Furihata K, Ishida K, Yan J, Kitano K, Kiyosawa K, Furuta S. The largest variant of platelet glycoprotein Ib has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine¹⁴⁵. Blood. 1995; 86: 1356–1360.

14. Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation. 1997; 96: 3281–3286.[Abstract/Free Full Text]

15. Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet membrane glycoprotein Ib alpha associated with arterial thrombotic disease. Blood. 1998; 92: 2771–2776.[Abstract/Free Full Text]

16. Kuijpers RWAM, Faber NM, Cuypers HTM, Ouwehand WH, Von dem Borne AEGK. NH₂-Terminal globular domain of human platelet glycoprotein Ib has a methionine¹⁴⁵/threonine¹⁴⁵ amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens. J Clin Invest. 1992; 89: 381–384.[Medline] [Order article via Infotrieve]

17. Murata M, Furihata K, Ishida F, Russell SR, Ware J, Ruggeri ZM. Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib involved in platelet transfusion refractoriness. Blood. 1992; 79: 3086–3090.[Abstract/Free Full Text]

18. Sonoda A, Murata M, Ito D, Tanahashi N, Ohta A, Tada Y, Takeshita E, Yoshida T, Saito I, Yamamoto M, Ikeda Y, Fukuuchi Y, Watanabe K. Association between platelet glycoprotein Ib alpha genotype and ischemic cerebrovascular disease. Stroke. 2000; 31: 493–497.[Abstract/Free Full Text]

19. Ito T, Ishida T, Shimodaira S, Kitano K. Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int J Hematol. 1999; 70: 47–51.[Medline] [Order article via Infotrieve]

20. Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S, Maurer G, Mayr WR, Panzer S. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res. 1998; 90: 117–123.[CrossRef][Medline] [Order article via Infotrieve]

21. Chen F, Jian Z, Xie Q, Pu X, Xiao B. Genetic polymorphism on HPA in chinese patients with acute myocardial infarction and acute ischemic stroke. Thromb Haemost. 1999; 82 (suppl): 157.Abstract.

22. Hato T, Minamoto Y, Fukuyama T, Fujita S. Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol. 1997; 80: 1222–1224.[CrossRef][Medline] [Order article via Infotrieve]

23. Hooper WC, Benson J, Jamil MEL, Dilley A, Wenger NK, Evatt BL. The lack of an association of the HPA-2B polymorphism of the glycoprotein Ib-alpha gene and the Glu298asp variant of the endothelial cell nitric oxide synthase gene with myocardial infarction in African-Americans. Thromb Haemost. 1999; 82 (suppl): 189.Abstract.

24. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999; 94: 46–51.[Abstract/Free Full Text]

25. Baker R, Lofthouse E, Staples N, Shen Y, Berndt MC, Lopez JA, Sadler S, Hankey G. Platelet glycoprotein (GP) Ib polymorphisms and risk of stroke. Thromb Haemost. 1999; 82 (suppl): 2680.Abstract.

26. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke. 1997; 28: 1392–1395.[Abstract/Free Full Text]

27. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa PIA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol. 1998; 18: 1124–1131.[Abstract/Free Full Text]

28. Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, Lopez JA. Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. Blood. 1999; 94: 186–191.[Abstract/Free Full Text]

29. Kaski S, Kekomaki R, Partanen J. Systematic screening for genetic polymorphism in human platelet glycoprotein Ib alpha. Immunogenetics. 1996; 44: 170–176.[CrossRef][Medline] [Order article via Infotrieve]

30. Santoso S, Zimmerman P, Sachs UJH, Gardemann A. The Kozak sequence polymorphism of the glycoprotein IBalpha gene is associated with the extent of coronary artery disease in younger patients. Blood. 2000; 96: 624a.Abstract.

31. Sonoda A, Murata M, Ikeda Y, Fukuuchi Y, Watanabe K. Stroke and platelet glycoprotein Ib polymorphisms. Thromb Haemost. 2001; 85: 573–574.[Medline] [Order article via Infotrieve]

32. Peterson ET, Sutherland R, Robinson DL, Chasteen L, Gersh M, Overhauser J, Deaven LL, Moyzis RK, Grady L. An integrated physical map for the short arm of human chromosome 5. Genome Res. 1999; 9: 1250–1267.[Abstract/Free Full Text]

33. Jaspers M, Marynen P, Aly MS, Cuppens H, Hilliker C, Cassiman JJ. Localization of the gene encoding the alpha 2 subunit of the human VLA-2 receptor to chromosome 5q23–31. Somat Cell Mol Genet. 1991; 17: 505–511.[CrossRef][Medline] [Order article via Infotrieve]

34. Takada Y, Hemler ME. The primary structure of the VLA-2/collagen receptor alpha 2 subunit (platelet GPIa): homology to other integrins and the presence of a possible collagen-binding domain. J Cell Biol. 1989; 109: 397–407.[Abstract/Free Full Text]

35. Ignatius MJ, Large TH, Houde M, Tawil JW, Barton A, Esch S, Carbonetto S, Reichardt LF. Molecular cloning of the rat integrin a1 subunit: a receptor for laminin and collagen. J Cell Biol. 1990; 111: 709–720.[Abstract/Free Full Text]

36. Cole JL, Marzec UM, Gunthel CJ, Karpatkin S, Worford L, Sundell IB, Lennox JL, Nichol JL, Harker LA. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood. 1998; 91: 3239–3246.[Abstract/Free Full Text]

37. Tomer A, Scharf RE, McMillan R, Ruggeri ZM, Harker LA. Bernard-Soulier syndrome: quantitative characterization of megakaryocytes and platelets by flow cytometric and platelet kinetic measurements. Eur J Haematol. 1994; 52: 193–200.[Medline] [Order article via Infotrieve]

38. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin ₂ß₁ copy number is associated with two silent polymorphisms in the ₂ gene coding sequence. Blood. 1997; 89: 1939–1943.[Abstract/Free Full Text]

39. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha 2 gene define multiple alleles which are associated with differences in platelet alpha 2 beta 1. Blood. 1998; 92: 2382–2388.[Abstract/Free Full Text]

40. Santoso S, Kalb R, Walka V, Kiefel V, Mueller-Eckhardt C, Newman PJ. The human platelet alloantigens Br(a) and Br(b) are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit 2). J Clin Invest. 1993; 92: 2427–2432.[Medline] [Order article via Infotrieve]

41. Santoso S, Amrhein J, Sachs U, Walka MM, Kroll H, Kiefel V. A mutational hot spot Thr₇₉₉Met on the ₂ integrin subunit leads to the formation of new human platelet alloantigen Sit^a and affects collagen-induced aggregation. Blood. 1997; 90: 261a.Abstract.

42. Zutter MM, Santoro SA, Painter AS, Tsung YL, Gafford A. The human ₂ integrin gene promoter. Identification of positive and negative regulatory elements important for cell-type and developmentally restricted gene expression. J Biol Chem. 1994; 269: 463–469.[Abstract/Free Full Text]

43. Zutter MM, Painter AA, Staatz WD, Tsung YL. Regulation of ₂ integrin gene expression in cells with megakaryocytic features: A common theme of three necessary elements. Blood. 1995; 86: 3006–3014.[Abstract/Free Full Text]

44. Zutter MM, Ryan EE, Painter AD. Binding of phosphorylated Sp1 protein to tandem Sp1 binding sites regulates alpha2 integrin gene core promoter activity. Blood. 1997; 90: 678–689.[Abstract/Free Full Text]

45. Jacquelin B, Rozenshteyn D, Kanaji S, Koziol JA, Nurden AT, Kunicki TJ. Characterization of inherited differences in transcription of the human integrin ₂ gene. J Biol Chem. 2001; 276: 23518–23524.[Abstract/Free Full Text]

46. Jacquelin B, Tarantino M, Kritzik M, Rozenshteyn D, Koziol JA, Kunicki TJ. Allele-dependent transcriptional regulation of the human integrin alpha 2 gene. Blood. 2001; 97: 1721–1726.[Abstract/Free Full Text]

47. Zutter MM, Painter AD, Yang X. The megakaryocyte/platelet-specific enhancer of the alpha 2 beta 1 integrin gene: two tandem AP1 sites and the mitogen-activated protein kinase signaling cascade. Blood. 1999; 93: 1600–1611.[Abstract/Free Full Text]

48. Di Paola J, Federici AB, Sacchi E, Canciani MT, Mannucci PM, Kritzik M, Kunicki TJ, Nugent DJ. Low platelet alpha 2 beta 1 levels in Type I von Willebrand Disease correlate with impaired platelet function in a high shear stress system. Blood. 1999; 93: 3578–3582.[Abstract/Free Full Text]

49. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C₈₀₇T gene polymorphism with myocardial infarction in younger patients. Blood. 1999; 93: 2449–2453.[Abstract/Free Full Text]

50. Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet. 1999; 353: 351–354.[CrossRef][Medline] [Order article via Infotrieve]

51. Roest M, Banga JD, Grobbee DE, De Groot PG, Sixma JJ, Tempelman MJ, van Der Schouw YT. Homozygosity for 807 T polymorphism in ₂ subunit of platelet ₂ß₁ is associated with increased risk of cardiovascular mortality in high-risk women. Circulation. 2000; 102: 1645–1650.[Abstract/Free Full Text]

52. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha 2 gene coding sequences T₈₀₇/A₈₇₃ of the platelet collagen receptor integrin alpha2 beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood. 1999; 93: 3583–3586.[Abstract/Free Full Text]

53. Matsubara Y, Murata M, Maruyama T, Handa M, Yamagata N, Watanabe G, Saruta T, Ikeda Y. Association between diabetic retinopathy and genetic variations in ₂ß₁ integrin, a platelet receptor for collagen. Blood. 2000; 95: 1560–1564.[Abstract/Free Full Text]

54. Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ, Daly ME. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol. 1999; 106: 771–776.[CrossRef][Medline] [Order article via Infotrieve]

55. Morita H, Kurihara H, Imai Y, Sugiyama T, Hamada C, Sakai E, Mori M, Nagai R. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and myocardial infarction in Japanese: an approach entailing melting curve analysis with specific fluorescent hybridization probes. Thromb Haemost. 2001; 85: 226–230.[Medline] [Order article via Infotrieve]

56. Anvari A, Janisiw M, Turel Z, Huber K, Fischer G, Panzer S. Platelet glycoprotein Ia gene dimorphism alpha2–807 in malignant arrhythmia in coronary artery disease. Thromb Res. 2000; 98: 281–286.[CrossRef][Medline] [Order article via Infotrieve]

57. Kroll H, Gardemann A, Fechter A, Haberbosch W, Santoso S. The impact of the glycoprotein Ia collagen receptor subunit A1648G gene polymorphism on coronary artery disease and acute myocardial infarction. Thromb Haemost. 2000; 83: 392–396.[Medline] [Order article via Infotrieve]

58. Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphisms of the ₂ gene in platelet GP Ia collagen receptor expression and function. Thromb Haemost. 1999; 81: 951–956.[Medline] [Order article via Infotrieve]

59. Carlsson LE, Potzsch B, Santoso S, Greinacher A. The GPIa-C807T polymorphism on the platelet collagen receptor GPIa-IIa and the development of deep vein thrombosis. Thromb Haemost. 1999; 82 (suppl): 254.Abstract.

60. Dinauer DM, Friedman KD, Hessner MJ. Allelic distribution of the glycoprotein Ia (alpha2-integrin) C807T/G873A dimorphisms among Caucasian venous thrombosis patients and six racial groups. Br J Haematol. 1999; 107: 563–565.[CrossRef][Medline] [Order article via Infotrieve]

61. Moroi M, Okuma M, Jung SM. Platelet adhesion to collagen-coated wells: analysis of this complex process and a comparison with the adhesion to matrigel-coated wells. Biochim Biophys Acta Mol Cell Res. 1992; 1137: 1–9.[Medline] [Order article via Infotrieve]

62. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest. 1989; 84: 1440.[Medline] [Order article via Infotrieve]

63. Sugiyama T, Okuma M, Ushibuki F, Sensaki S, Kanaji K, Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood. 1987; 69: 1712–1720.[Abstract/Free Full Text]

64. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, Tybulewicz VL, Watson SP. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 1997; 16: 2333–2341.[CrossRef][Medline] [Order article via Infotrieve]

65. Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett. 1997; 413: 255–259.[CrossRef][Medline] [Order article via Infotrieve]

66. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem. 1997; 272: 23528–23531.[Abstract/Free Full Text]

67. Gibbins J, Asselin J, Farndale R, Barnes M, Law CL, Watson SP. Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. J Biol Chem. 1996; 271: 18095–18099. Abstract.[Abstract/Free Full Text]

68. Morton LF, McCulloch IY, Barnes MJ. Platelet aggregation by a collagen-like synthetic peptide. Thromb Res. 1993; 72: 367–372.[CrossRef][Medline] [Order article via Infotrieve]

69. Asselin J, Gibbins JM, Achison M, Lee YH, Morton LF, Farndale RW, Barnes MJ, Watson SP. A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase Cy 2 in platelets independent of the integrin ₂ß₁. Blood. 1997; 89: 1235–1242.[Abstract/Free Full Text]

70. Polgar J, Clemetson JM, Kehrel BE, Wiedemann M, Magnenat EM, Wells TNC, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus Durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem. 1997; 272: 13576–13583.[Abstract/Free Full Text]

71. Jandrot-Perrus M, Lagrue AH, Okuma M, Bon C. Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin ₂ß₁. J Biol Chem. 1997; 272: 27035–27041.[Abstract/Free Full Text]

72. Clemetson JM, Polgar J, Magnenat E, Wells TNC, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcR and the natural killer receptors. J Biol Chem. 1999; 274: 29019–29024.[Abstract/Free Full Text]

73. Furihata K, Clemetson KJ, Deguchi H, Kunicki TJ. Variation in human platelet GPVI content modulates GPVI-specific prothrombinase activity. Arterioscler Thromb Vasc Biol. 2001; 21: 1857–1863.[Abstract/Free Full Text]

74. Lagrue-Lak-Hal AH, Debili N, Kingbury G, Lecut C, Le Couedic JP, Villeval JL, Jandrot-Perrus M, Vainchenker W. Expression and function of the collagen receptor GPVI during megakaryocyte maturation. J Biol Chem. 2001; 276: 15316–15325.[Abstract/Free Full Text]

75. Chiang TM, Kang AH. A synthetic peptide derived from the sequence of a type I collagen receptor inhibits type I collagen-mediated platelet aggregation. J Clin Invest. 1997; 100: 2079–2084.[Medline] [Order article via Infotrieve]

76. Chiang TM, Wang YB, Kang ES. Role of the recombinant protein of the platelet receptor for type I collagen in the release of nitric oxide during platelet aggregation. Thromb Res. 2000; 100: 427–432.[CrossRef][Medline] [Order article via Infotrieve]

77. Chiang TM, Rinaldy A, Kang AH. Cloning, characterization, and functional studies of a nonintegrin platelet receptor for type I collagen. J Clin Invest. 1997; 100: 514–521.[Medline] [Order article via Infotrieve]

78. Monnet E, Fauvel-Lafeve F. A new platelet receptor specific to type III collagen: type III collagen-binding protein. J Biol Chem. 2000; 275: 10912–10917.[Abstract/Free Full Text]

79. Moog S, Mangin P, Lenain N, Strassel C, Ravanat C, Schuhler S, Freund M, Santer M, Kahn M, Nieswandt B, et al. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood. 2001; 98: 1038–1046.[Abstract/Free Full Text]

80. Sacchi E, Tagliabue L, Duca F, Landi G, Martinelli I, Mannucci PM. A C807T substitution in the coding sequence of the platelet collagen receptor integrin 1 as a genetic risk factor for stroke in young patients. Thromb Haemost. 1999; 82 (suppl): 848.Abstract,

81. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke. 2000; 31: 1628–1633.[Abstract/Free Full Text]

82. Hessner MJ, Dinauer DM, Luhm RA, Endres JL, Montgomery RR, Friedman KD. Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691 GA (Leiden) carriers. Br J Haematol. 1999; 106: 237–239.[CrossRef][Medline] [Order article via Infotrieve]

83. von Beckerath N, Koch W, Mehilli J, Bottiger C, Schomig A, Kastrati A. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood. 2000; 95: 3297–3301.[Abstract/Free Full Text]

This article has been cited by other articles:

				F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1041 - 1057. [Abstract] [Full Text] [PDF]

				C. I. Jones, S. Bray, S. F. Garner, J. Stephens, B. de Bono, W. G. J. Angenent, D. Bentley, P. Burns, A. Coffey, P. Deloukas, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways Blood, August 13, 2009; 114(7): 1405 - 1416. [Abstract] [Full Text] [PDF]

				J. P. Corsetti, D. Ryan, A. J. Moss, D. L. Rainwater, W. Zareba, and C. E. Sparks Glycoprotein Ib{alpha} Polymorphism T145M, Elevated Lipoprotein-Associated Phospholipase A2, and Hypertriglyceridemia Predict Risk for Recurrent Coronary Events in Diabetic Postinfarction Patients Diabetes, May 1, 2007; 56(5): 1429 - 1435. [Abstract] [Full Text] [PDF]

				L. Navarro-Nunez, M. L. Lozano, J. Rivera, J. Corral, V. Roldan, R. Gonzalez-Conejero, J. A. Iniesta, J. Montaner, V. Vicente, and C. Martinez The association of the {beta}1-tubulin Q43P polymorphism with intracerebral hemorrhage in men Haematologica, April 1, 2007; 92(4): 513 - 518. [Abstract] [Full Text] [PDF]

				M. Ogino, J. Kido, M. Bando, N. Hayashi, C. Wada, T. Nagata, F. Nishimura, Y. Soga, S. Takashiba, T. Kubota, et al. {alpha}2 Integrin +807 Polymorphism in Drug-induced Gingival Overgrowth Journal of Dental Research, December 1, 2005; 84(12): 1183 - 1186. [Abstract] [Full Text] [PDF]

				T. J. Kunicki, A. B. Federici, D. R. Salomon, J. A. Koziol, S. R. Head, T. S. Mondala, J. D. Chismar, L. Baronciani, M. T. Canciani, and I. R. Peake An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees Blood, October 15, 2004; 104(8): 2359 - 2367. [Abstract] [Full Text] [PDF]

				M. J. Coffey, G. E. Jarvis, J. M. Gibbins, B. Coles, N. E. Barrett, O. R.E. Wylie, and V. B. O'Donnell Platelet 12-Lipoxygenase Activation via Glycoprotein VI: Involvement of Multiple Signaling Pathways in Agonist Control of H(P)ETE Synthesis Circ. Res., June 25, 2004; 94(12): 1598 - 1605. [Abstract] [Full Text] [PDF]

				Z. Wang, T. M. Leisner, and L. V. Parise Platelet {alpha}2{beta}1 integrin activation: contribution of ligand internalization and the {alpha}2-cytoplasmic domain Blood, August 15, 2003; 102(4): 1307 - 1315. [Abstract] [Full Text] [PDF]

				O. Inoue, K. Suzuki-Inoue, W. L. Dean, J. Frampton, and S. P. Watson Integrin {alpha}2{beta}1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLC{gamma}2 J. Cell Biol., March 3, 2003; 160(5): 769 - 780. [Abstract] [Full Text] [PDF]

				A. Dupont, P. Fontana, C. Bachelot-Loza, J.-L. Reny, I. Bieche, F. Desvard, M. Aiach, and P. Gaussem An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN Blood, March 1, 2003; 101(5): 1833 - 1840. [Abstract] [Full Text] [PDF]

				K. Furihata and T. J. Kunicki Characterization of Human Glycoprotein VI Gene 5' Regulatory and Promoter Regions Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1733 - 1739. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kunicki, T. J. Search for Related Content PubMed PubMed Citation Articles by Kunicki, T. J. Related Collections Arterial thrombosis Thrombosis risk factors Platelets